Clinical-stage Drug Candidates

Category Candidate Target Indication Preclinical IND Phase I Phase II Registration Trial Application Progress* and Upcoming Milestone Partner
Oncology and autoimmune diseases MIL62 Third-generation CD20
(ADCC-enhanced)
Follicular lymphoma(FL)
Relapsed/refractory
Phase III registration trial
(recruiting patients)
Follicular lymphoma(FL)
Untreated
Phase III registration trial application(communicating with CDE)
Diffuse large B-cell lymphoma(DLBCL)
Relapsed/refractory
Phase I/IIa trial (recruitment completed) InnoCare
B cell non-Hodgkin lymphoma
Phase II trial(approved by NMPA)
Lupus nephritis (LN)
Phase Ib/II trial (recruiting patients)
Primary membranous nephropathy (PMN)
Phase Ib/II trial (recruiting patients)
Neuromyelitis optical spectrum disorder (NMOSD)
Phase Ib/III trial (recruiting patients)
Myasthenia gravis (MG)
Phase II trial
Systemic Lupus Erythematosus(SLE)
Phase II/III trial(approved by NMPA)
MIL93 Claudin 18.2
(ADCC-enhanced)
Claudin 18.2-positive gastric cancer, gastroesophageal junction cancer and pancreatic cancer
Phase I trial (recruiting patients)
MIL95 CD47 Lymphoma and advanced solid tumors
Phase I trial (recruiting completed) Keymed
MIL97 CD40 Metastatic pancreatic cancer and other solid tumors
Phase I trial(approved by NMPA)
MBS301 HER2/HER2
(ADCC-enhanced bispecific antibody)
HER2-positive metastatic gastric cancer and other solid tumors
Phase I trial (recruiting patients)
MIL98 LAG3 Melanoma, late-stage lymphoma and other late-stage malignant solid tumors
Phase I trial (recruiting patients)
Others MIL86 PCSK9 Hyperlipidemia
Phase II trial (recruiting completed)

OncologyAutoimmune diseasesPlanned trial to be initiatedOthers

Selected Preclinical Drug Candidates

Category Candidate Target Indication Preclinical IND Phase I Phase II Registration Trial Application Progress* and Upcoming Milestone Partner
Oncology and autoimmune diseases MBS303 CD3-CD20 B cell non-Hodgkin lymphoma
Preliminary research and development
MBS304 CD3/Claudin 18.2 Gastric cancer and pancreatic cancer
Preliminary research and development
MBS307 PD-L1/CD40 Solid tumors
Preliminary research and development
MBS309 PD-1/IL-2 Solid tumors
Preliminary research and development
MBS314 GPRC5D-CD3-BCMA Multiple Myeloma(MM)
Preliminary research and development KYinno